Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer
April 19, 2024 01:00 ET
|
Nykode Therapeutics ASA
OSLO, Norway, April 19, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer
March 21, 2024 02:00 ET
|
Nykode Therapeutics ASA
Updated survival data from Phase 2 trial (C-02) in advanced cervical cancer affirm prolonged benefits and indicate a synergistic treatment effect of Nykode’s VB10.16 and atezolizumab (Tecentriq®).New...
Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases
March 19, 2024 02:00 ET
|
Nykode Therapeutics ASA
OSLO, Norway, March 19, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode Therapeutics - Quarterly report Q3 2023
November 15, 2023 04:30 ET
|
Nykode Therapeutics ASA
OSLO, Norway, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode Therapeutics to Present at the mRNA Cancer Vaccines Summit 2023 in Boston
October 09, 2023 00:45 ET
|
Nykode Therapeutics ASA
Nykode’s APC targeted vaccine technology can be delivered as mRNA and generate strong T cell responsesNykode’s APC targeted vaccine technology consistently results in faster, broader and stronger...
Nykode Therapeutics Announces Advances in Clinical Pipeline and Research
September 20, 2023 10:06 ET
|
Nykode Therapeutics ASA
On-track to leverage promising Phase 2 cervical cancer data with FDA clearance to start a potentially registrational trial in 2023, and expansion into head and neck, two areas with high unmet...
Nykode Therapeutics Announces FDA Approval of IND for VB-C-04, a Trial of VB10.16 in HPV16-Positive Cervical Cancer
September 05, 2023 01:00 ET
|
Nykode Therapeutics ASA
FDA approval of IND for VB-C-04 trial.Nykode to further elaborate on trial design and development strategy at upcoming capital markets day in New York on September 20. OSLO, Norway, Sept. 05,...
Nykode Therapeutics - Quarterly report Q2 2023
August 23, 2023 00:45 ET
|
Nykode Therapeutics ASA
OSLO, Norway, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...